Anti-DcR2抗体(ab2019)
Key features and details
- Rabbit polyclonal to DcR2
- Suitable for: ICC, WB
- Reacts with: Mouse, Rat, Human
- Isotype: IgG
概述
-
产品名称
Anti-DcR2抗体
参阅全部 DcR2 一抗 -
描述
兔多克隆抗体to DcR2 -
宿主
Rabbit -
特异性
Human, Mouse, Rat -
经测试应用
适用于: ICC, WBmore details -
种属反应性
与反应: Mouse, Rat, Human -
免疫原
Synthetic peptide corresponding to Human DcR2 aa 249-263.
Sequence:GGPERVHRVLFRRRS
(Peptide available asab8379) -
常规说明
Decoy Receptor 2 for TRAIL
性能
-
形式
Liquid -
存放说明
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
存储溶液
pH: 7.2
Preservative: 0.02% Sodium azide -
Concentration information loading... -
纯度
Immunogen affinity purified -
克隆
多克隆 -
同种型
IgG -
研究领域
相关产品
-
Compatible Secondaries
-
Isotype control
应用
Our Abpromise guarantee covers the use of ab2019 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
| 应用 | Ab评论 | 说明 |
|---|---|---|
| ICC | Use a concentration of 10 µg/ml. | |
| WB | 1/1000 - 1/2000. |
靶标
-
功能
Receptor for the cytotoxic ligand TRAIL. Contains a truncated death domain and hence is not capable of inducing apoptosis but protects against TRAIL-mediated apoptosis. Reports are contradictory with regards to its ability to induce the NF-kappa-B pathway. According to PubMed:9382840, it cannot but according to PubMed:9430226, it can induce the NF-kappa-B pathway. -
组织特异性
Widely expressed, in particular in fetal kidney, lung and liver, and in adult testis and liver. Also expressed in peripheral blood leukocytes, colon and small intestine, ovary, prostate, thymus, spleen, pancreas, kidney, lung, placenta and heart. -
序列相似性
Contains 1 death domain.
Contains 3 TNFR-Cys repeats. -
细胞定位
Membrane. - Information by UniProt
-
数据库链接
- Entrez Gene: 8793 Human
- Omim: 603614 Human
- SwissProt: Q9UBN6 Human
- Unigene: 213467 Human
-
别名
- CD 264 antibody
- CD264 antibody
- DcR 2 antibody
see all
图片
-
Western blot - Anti-DcR2 antibody (ab2019)Anti-DcR2 antibody (ab2019) at 1/1000 dilution + HeLa whole cell lysate
Observed band size: 35 kDa why is the actual band size different from the predicted? -
Immunocytochemistry - Anti-DcR2 antibody (ab2019)ab2019 at 10µg/ml staining DcR2 in human Hela cells by Immunocytochemistry.
实验方案
数据表及文件
文献 (10)
ab2019 被引用在 10 文献中.
- Wang Z et al. Enhancing the antitumor activity of an engineered TRAIL-coated oncolytic adenovirus for treating acute myeloid leukemia. Signal Transduct Target Ther 5:40 (2020). PubMed: 32327638
- Brunetti G et al. High expression of TRAIL by osteoblastic differentiated dental pulp stem cells affects myeloma cell viability. Oncol Rep 39:2031-2039 (2018). PubMed: 29484421
- You C et al. ß-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors. Int J Oncol 53:2258-2268 (2018). PubMed: 30132512
- Chung SI et al. Comparison of liver oncogenic potential among human RAS isoforms. Oncotarget 7:7354-66 (2016). PubMed: 26799184
- Laine A et al. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1. Cancer Discov 3:182-97 (2013). Human . PubMed: 23306062
- Yu M et al. Inactivation of TGF-ß signaling and loss of PTEN cooperate to induce colon cancer in vivo. Oncogene N/A:N/A (2013). Mouse . PubMed: 23604118
- Fan LC et al. a-Catulin knockdown induces senescence in cancer cells. Oncogene 30:2610-21 (2011). WB . PubMed: 21278790
- Anees M et al. Recurrence-free survival in prostate cancer is related to increased stromal TRAIL expression. Cancer 117:1172-82 (2011). PubMed: 21381010
- Emblom-Callahan MC et al. Genomic phenotype of non-cultured pulmonary fibroblasts in idiopathic pulmonary fibrosis. Genomics 96:134-45 (2010). WB ; Human . PubMed: 20451601
- Leithner K et al. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy. Lung Cancer 65:98-104 (2009). PubMed: 19081160
